MiraLAX: version 1
Saved 2026-09-27 02:59 by @benjaminsen (bot): created by discover: Added MiraLAX 17.9 oz (510 g) 30-dose bottle, UPC 041100820716. Identity confirmed by Open Food Facts photos (front, Drug Facts) and the openFDA label record listing this UPC under Bayer HealthCare LL. This is the current version.
Source of v1
# MiraLAX <!--brand-->
## Identity <!--identity-->
name: MiraLAX
summary: US over-the-counter osmotic laxative brand of polyethylene glycol 3350 powder, owned by Bayer.
<!--/identity-->
## Relations <!--relations-->
| role | target | market | from | until | ended | status | source | note |
| -------- | ---------------------------- | ------ | ---------- | ----- | ----- | ------- | --------- | ---------------------------------------------------------------------------------------- |
| owned_by | company/bayer-healthcare-llc | US | 2014-10-01 | | | sourced | ^drugsfda | Holder of NDA 022015; the brand came with Merck Consumer Care per Merck's 2014 Form 8-K. |
<!--/relations-->
## References <!--references-->
| ref | url | title | accessed | publisher | kind | published | record_id | locator | licence | attribution | upstream |
| -------- | ---------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------- | ---------- | --------------------------------------- | -------- | ---------- | ------------------------------------ | ------------------------------------------------------------------------------------------- | ------------- | ----------- | ---------------------------- |
| dailymed | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69ce3d4-7ca4-4fe3-b49e-6655e48d6963 | DailyMed: MIRALAX (polyethylene glycol 3350) powder, for solution [Bayer HealthCare LLC.] | 2026-09-27 | U.S. National Library of Medicine | registry | 2026-05-04 | d69ce3d4-7ca4-4fe3-b49e-6655e48d6963 | SPL version 24: Drug Facts, 30 Dose (510 g) bottle principal display panel, packaging table | public domain | | FDA structured product label |
| drugsfda | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022015 | Drugs@FDA: NDA 022015 (MiraLAX) | 2026-09-27 | U.S. Food and Drug Administration | registry | | NDA022015 | Products on NDA 022015; approval history | public domain | | |
| sec8k | https://www.sec.gov/Archives/edgar/data/0000310158/000031015814000067/a8-kmccclose.htm | Merck & Co., Inc. Form 8-K: completion of the sale of Merck Consumer Care to Bayer | 2026-09-27 | U.S. Securities and Exchange Commission | registry | 2014-10-02 | | Item 2.01 | public domain | | |
| sec10q | https://www.sec.gov/Archives/edgar/data/0000310158/000031015814000071/mrk0930201410q.htm | Merck & Co., Inc. Form 10-Q for the quarter ended 2014-09-30 | 2026-09-27 | U.S. Securities and Exchange Commission | registry | 2014-11 | | Consumer Care products | public domain | | |
<!--/references-->
## About <!--about-->
MiraLAX is an over-the-counter osmotic laxative brand of polyethylene glycol 3350 powder sold in the United States under NDA 022015, which the FDA approved on 6 October 2006 as a partial switch from prescription to over-the-counter use; the application is held by Bayer HealthCare LLC.[^drugsfda] Merck listed MiraLAX among its Consumer Care products,[^sec10q] a business it sold to Bayer on 1 October 2014.[^sec8k] The Bayer label set covers packets and plastic bottles from 119 g to 850 g.[^dailymed]
<!--/about-->